Back to NAI500

Company Profile

XORTX Therapeutics Inc. is a biotechnology company with three drug development programs, two of which are clinically advanced products under development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products – XRx-008 and XRx-101 – that target xanthine oxidase to inhibit production of uric acid. The Company has a growing portfolio of intellectual property and in some cases claims within granted patents has established proof of concept through independent clinical studies.

Corporate Speaker

Allen Davidoff

CEO

Dr. Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies (four of which were multi-country), seven phase II studies, and one NDA. Prior to forming XORTX, Allen was the Chief Scientific Officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. (seven years) (Trillium TRIL: NASDAQ) and Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp.

Company Website

Stock Info:

NASDAQ: XRTX, TSXV: XRTX, FRA: ANU